基本信息
浏览量:794
职业迁徙
个人简介
Dr. Ballantyne's clinical research focuses on the prevention of cardiometabolic disease. This interest includes pharmacological studies to assess the efficacy and benefits of lipid-lowering drug therapy including trials that examine the effects of lipid-lowering drugs on cardiovascular disease events and the progression of atherosclerosis. As the director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory, which serves as the core laboratory for the Atherosclerosis Risk in Communities study, Dr. Ballantyne is studying whether genetic variants in combination with novel biomarkers might be useful in identifying individuals at high risk for cardiometabolic disease and diabetes. Genomics, proteomics, and metabolomics are being used to identify novel molecules that are increased with atherosclerosis, obesity, diabetes, and cardiometabolic disease. In addition, his group is studying new approaches to the prevention and treatment of cardiometabolic diseases with the goal of developing personalized diet, lifestyle, and pharmacotherapy based on the genetic profile and clinical phenotype assessed by proteomics, metabolomics, and imaging.
研究兴趣
论文共 2018 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Current Atherosclerosis Reportspp.1-6, (2024)
Elsevier eBookspp.268-274.e1, (2024)
引用0浏览0引用
0
0
Journal of the American College of Cardiologyno. 13 (2024): 1683
Nature Medicineno. 3 (2024): 810-817
JAMA NETWORK OPENno. 1 (2024): e2351927-e2351927
Elsevier eBookspp.79-87.e2, (2024)
Christie M. Ballantyne, Tyler Varisco,Timothy Graham, Bruce J. Iteld, Harvey Serota, Sean McElligott, Xiaoli Niu, Kelly Hanna,Lucinda Van Anglen
Journal of the American College of Cardiologyno. 13 (2024): 1941
EUROPEAN HEART JOURNAL (2024)
AMERICAN JOURNAL OF MEDICINEno. 2 (2024): 122-127.e1
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn